Drug Information

   


        













Pharmacokinetics


It is administered as infusion. After infusion it undergoes intensive
P450-mediated hepatic metabolism. The clearance of Paclitaxel is
saturable and decreases with increasing dose or dose rate.


Top

    

Indication
& Dosage




Metastatic ovarian and breast cancer

Dosage: Adults: 175mg per square metre by i.v. inf. over 3 hrs. Repeat
every week 3 weeks. Pretreat with conticosteroids.

Children: Not recommended.

Top

    

Action

Naturally occurring antineoplastic agent that promotes the assembly
of microtubules from tubulin dimers and stabilizes microtubules by
preventing depolymerization. The stabilization results in the inhibition
of the normal dynamic reorganization of the microtubule network that is
required for vital interphase and mitotic cellular functions. Also
induces abnormal “bundles” of microtubules throughout the cell cycle
and multiple esters of microtubules during mitosis. Following IV
administration, there is a biphasic decline in plasma levels. The
initial rapid decline is due to distribution to the peripheral
compartment and significant elimination, whereas the second phase is
due, in part, to a slow efflux of the drug from the peripheral
compartment. Metabolized by the liver with small amounts of unchanged
drug excreted in the urine.

Top

    

Interaction

Cisplatin / More profound myelosuppression when paclitaxel was
given after cisplatin than when paclitaxel was given before cisplatin,
due to a 1/3 decrease in paclitaxel clearance

Doxorubicin /
Levels of doxorubicin and doxorubicinol


Ketoconazole / Inhibition of metabolism of paclitaxel by
ketoconazole

Top

    

Adverse
Effect & Precautions






Bone marrow depression,
hypersensitivity reactions, myalgia, chest pain, bradycardia, a
stocking-glove sensory neuropathy, mucositis, nausea, vomiting,
diarrhoea, alopecia. Altered liver function tests.



Precaution: Safety and efficacy in children has not been established.
Monitor haematological functions. The drug should be administered under
supervision of a physician experienced in use of cancer chemotherapy

Pregnancy: Use with caution

Breast Feeding: Discontinue nursing

Man: Use with caution

Top

    






 






 

    

   
Drug Information
   

        

Pharmacokinetics

It is administered as infusion. After infusion it undergoes intensive P450-mediated hepatic metabolism. The clearance of Paclitaxel is saturable and decreases with increasing dose or dose rate.

Top
    

Indication & Dosage

Metastatic ovarian and breast cancer
Dosage: Adults: 175mg per square metre by i.v. inf. over 3 hrs. Repeat every week 3 weeks. Pretreat with conticosteroids.
Children: Not recommended.

Top
    

Action

Naturally occurring antineoplastic agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. The stabilization results in the inhibition of the normal dynamic reorganization of the microtubule network that is required for vital interphase and mitotic cellular functions. Also induces abnormal “bundles” of microtubules throughout the cell cycle and multiple esters of microtubules during mitosis. Following IV administration, there is a biphasic decline in plasma levels. The initial rapid decline is due to distribution to the peripheral compartment and significant elimination, whereas the second phase is due, in part, to a slow efflux of the drug from the peripheral compartment. Metabolized by the liver with small amounts of unchanged drug excreted in the urine.

Top
    

Interaction

Cisplatin / More profound myelosuppression when paclitaxel was given after cisplatin than when paclitaxel was given before cisplatin, due to a 1/3 decrease in paclitaxel clearance Doxorubicin / Levels of doxorubicin and doxorubicinol Ketoconazole / Inhibition of metabolism of paclitaxel by ketoconazole

Top
    

Adverse Effect & Precautions

Bone marrow depression, hypersensitivity reactions, myalgia, chest pain, bradycardia, a stocking-glove sensory neuropathy, mucositis, nausea, vomiting, diarrhoea, alopecia. Altered liver function tests.

Precaution: Safety and efficacy in children has not been established. Monitor haematological functions. The drug should be administered under supervision of a physician experienced in use of cancer chemotherapy
Pregnancy: Use with caution
Breast Feeding: Discontinue nursing
Man: Use with caution

Top
    


 

 

By |2022-07-20T16:42:53+00:00July 20, 2022|Uncategorized|Comments Off on Paclitaxel

About the Author: